anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Investigators will conduct a randomized controlled trial to examine whether vitamin D3 supplementation can improve depressive symptoms. A total of 310 participants will be recruited from two middle schools. Inclusion criteria are grades 7th and 8th students whose caregivers signed informed consents, self-reported mild and moderate depressive symptoms with scores of BDI-II\>13, and serum 25(OH)D concentration of 12-20 ng/mL. Exclusion criteria are the use of anti-psychotic treatments or interventions in the past 3 months; serious health conditions (e.g., major psychiatric disorders, serious infectious diseases, chronic gastrointestinal diseases, and hepatic or renal diseases); the use of vitamin D supplements in the past 3 months; self-reported suicidal plans/attempts in the past 3 months; intellectual disability. Participants will be randomly assigned into a supplementation or placebo group. Supplementation arm will receive oral dose 2000 IU vitamin D3 per day for 6 weeks and followed by 800 IU per day for 6 weeks; placebo arm will receive placebo every day for 12 weeks. Both of these two groups will receive additional mental health education. For the first 6 weeks, vitamin D or placebo will be administrated every two weeks. For the next 6 weeks, vitamin D or placebo will be administrated every three weeks. The primary outcome of this study is to compare the change of depressive symptoms between supplementation or placebo group from pre- to post-intervention at 12 weeks.
The invention discloses a novel oily liquid accessory (with an oil matrix) of a blood sugar-reduction soft capsule, and the novel oily liquid accessory is rice bran oil. Materials having drug effects are dissolved or uniformly mixed in the oily liquid accessory and the mixture is sealed in a hydrophilic gelatin capsule so that a finished capsule is obtained. Plant oil is widely used as an oily liquid accessory for preparation of content of the soft capsule. At present, use of rice bran oil as the oily liquid accessory of the blood sugar-reduction soft capsule has not been reported. Rice bran oil has unsaturated fatty acid content more than 80% and has a high nutritive value. Rice bran oil has relative density of 0.913-0.928 (at a temperature of 15/25 DEG C), can be used as the oily liquid accessory, has an absorption rate more than 90% after eating, and can promote soft capsule medicinal component absorption. Rice bran oil contains unique active compounds for reducing blood sugar and inhibiting diabetic nephropathy, can be used as the oily liquid accessory of the blood sugar-reduction soft capsule, can improve sugar-reduction effects of the blood sugar-reduction soft capsule and is the novel oily liquid accessory of the blood sugar-reduction soft capsule.
PURPOSE:To prepare a perfumery composition containing tamariscol extracted from Frullania tamarisci subsp. tamarisci, having fantastic aroma suggesting various kinds of smell, and strong diffusibility and retainability, and useful as a component of compounded perfumery. CONSTITUTION:The objective perfumery composition contains tamariscol [chemical name, 3,7-dimethyl-2-(2-methyl-1-propenyl)hexahydroindan-2-ol]. Tamariscol can be prepared e.g. by extracting dried and pulverized Frullania tamarisci subsp. tamarisci with a solvent such as methanol, chloroform, etc. It has been found newly that tamariscol has woody note and powdery-green note as the base note, and fantastic aroma suggesting various aroma such as moss note, costus note, etc., harmonizes well many perfumery materials, and is useful as a component of compounded perfumery.
Tumor-associated peptide having a 9-17 residue amino acid sequence from the groups SEQ ID-No. 1-577 from a given sequence protocol. The peptide has the ability to bond with a molecule of the human class I major histocompatibility complex (MHC) proteins. At least one amino acid is chemically modified, or at least one amino acid is deleted, or at least one amino acid is replaced by another amino acid with similar chemical characteristics. Tumor-associated peptide having a 9-17 residue amino acid sequence from the groups SEQ ID-No. 1-577 from a given sequence protocol. The peptide has the ability to bond with a molecule of the human class I major histocompatibility complex (MHC) proteins. At least one amino acid is chemically modified, or at least one amino acid is deleted, or at least one amino acid is replaced by another amino acid with similar chemical characteristics. The N and/or C terminal is available of at least one other amino acid. ACTIVITY : Cytostatic. No biological data is given. MECHANISM OF ACTION : None given.
1,261,493. Dentifrices containing barium sulphate. MEDISAN AB. 26 Feb., 1970 [27 Feb., 1969], No. 9215/70. Heading A5B. Dentifrices particularly pastes and creams comprise a mixture of pulverulent barium sulphate, a salt of an hydroxy acid capable of acting as a peptizing agent for the barium sulphate, one or more alkali metal fluorides such as sodium fluoride, and water. The peptizing agent may be a neutral salt for example alkali metal and ammonium salts of the hydroxy acid especially of poly-basic hydroxy carboxylic acids such as citric, tartaric and malic acids, carbonic acid and of pyrophosphoric acid. The dentifrice may also contain glycerol, sorbitol, a wetting agent such as sodium lauryl sulphoacetate or sodium lauryl sulphate and/or sodium chloride.
The invention comprises compounds of the general formula <FORM:0988634/C2/1> (wherein R represents a lower alkyl, alkenyl, alkynyl, hydroxyalkyl or cyanoalkyl group or an aralkyl group, R1 represents a lower alkyl, alkenyl or alkynyl group, R2 and R3 each represent a halogen atom or a lower alkyl group, and the broken lines denote that the R-substituents attached thereby are optional) and acid addition and quaternary salts thereof, pharmaceutical preparations containing them, and their preparation by (a) reacting a compound of the general formula <FORM:0988634/C2/2> with an appropriate alkylating, alkenylating or alkynylating agent, or (b)-in the case of compounds in which R is present and is a lower alkyl, alkenyl or alkynyl group-subjecting the sodio derivative of a starting material of the above general formula, but in which R is absent, to prolonged heating with at least two mols. of an appropriate alkylating, alkenylating or alkynylating agent and, if necessary, converting the product in either case into an acid addition or quaternary salt.  The terms "lower alkyl, alkenyl, alkynyl and hydroxyalkyl" denote groups containing up to seven carbon atoms, and the term "lower cyanoalkyl" denotes groups containing up to seven carbon atoms in the alkyl portion of the group.  The compounds of the invention are sedatives, muscle relaxants and anticonvulsants, and may be administered enterally (e.g. orally) or parenterally in the form of pharmaceutical preparations (e.g. tablets, dragees, suppositories, capsules, solutions, emulsions and suspensions) containing them, with or without other (unspecified) active ingredients, in admixture with a carrier.  Specifications 972,968 and 988,635 are referred to.
Teratogenic Effects

Disopyramide phosphate was associated with decreased numbers of implantation sites and decreased growth and survival of pups when administered to pregnant rats at 250 mg/kg/day (20 or more times the usual daily human dose of 12 mg/kg, assuming a patient weight of at least 50 kg), a level at which weight gain and food consumption of dams were also reduced. Increased resorption rates were reported in rabbits at 60 mg/kg/day (5 or more times the usual daily human dose). Effects on implantation, pup growth, and survival were not evaluated in rabbits. There are no adequate and well-controlled studies in pregnant women. Disopyramide phosphate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects

Disopyramide phosphate has been reported to stimulate contractions of the pregnant uterus. Disopyramide has been found in human fetal blood.
The invention discloses a traditional Chinese medicine composition for nourishing blood and its use in a mask product. The traditional Chinese medicine composition for nourishing blood comprises whole Chinese angelica, ligusticum wallichii, divaricate saposhnikovia root, ginkgo leaves and trichosanthes root according to a weight part ratio or an extract mixing ratio of 1: 1: 1: 1. The weighed powder ingredients are uniformly mixed through a mixer for next use. The uniformly mixed traditional Chinese medicine composition is traditional Chinese medicine mask powder which can be directly packaged and sold and can be blended in use, or can be mixed with bases such as white honey and purified water and then can be processed to form traditional Chinese medicine mask paste. Through traditional Chinese medicine cooperation, combination of inner adjustment and outer nutrient supplying is realized. The traditional Chinese medicine composition has effects of promoting blood circulation and moistening skin, improving skin color and treating and caring face skin of people with symptoms of dry skin, fine wrinkle, face color dinginess or yellowing, and qi, blood and yin deficiency.
Evaluation of the efficacy and safety of methylprednisolone combined with tofacitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with tofacitinib 10 mg daily.
Healthy pregnant women, between and including 18-40 years of age, at 24 0/7 through 34 6/7 weeks of gestation, with the intent to breastfeed, who received a single dose of Group B Streptococcus (GBS) trivalent vaccine, injected intramuscularly. (Pregnant women are referred to as maternal subjects as the study period spans from pregnancy to Day 180 postpartum).
The invention provides sweet potato ball formerly named Fu-qing ipomoea ball, which is O in shape and Q in character. The cot material is prepared by mixing appropriate starch mother and son dumpling into the natural healthy food sweet potato, pinching together, wraping various kinds of fillings and rounding. With the special preparation process, the cot is soft and palatable with Q toughness, and the fillings express respective functions. The sweet potato ball provided by the invention has good color and taste, complement each other's advantages, beautiful in appearance, balanced nutrition, and is easy to absorb, endless in aftertaste, and deeper in meaning, wherein kinds of tastes in the ball are not named king; and the sweet potato ball not only represents local flavor, but also represents deeper significance, which implies team spirit and togetherness. Pardon can generate cohesion, and consensus and synergy can realize successfully grand prospect. There is provided a common saying in civil society: every dog has his day, and the good luck comes when we eat the sweet potato ball. The science tells us, being kind to communicate, understanding rally, and being physical and psychological health, thus the good luck can be come with our dream.
Severe malaria remains a major cause of global morbidity and mortality. While the use of artemisinin-based antimalarial therapy has improved outcomes in severe malaria, the mortality rate remains high. Adjunctive therapies that target the underlying pathophysiology of severe malaria may further reduce morbidity and mortality. Endothelial activation plays a central role in the pathogenesis of severe malaria, of which the angiogenic factors angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) have recently been shown to function as key regulators. Nitric oxide (NO) is a major inhibitor of Ang-2 release from endothelium and has been shown to decrease endothelial inflammation and reduce the adhesion of parasitized erythrocytes. Low-flow inhaled nitric oxide gas (iNO) is a US FDA-approved treatment for hypoxic respiratory failure in neonates. Based on compelling data on the efficacy of iNO in experimental cerebral malaria in animal models, coupled with the documented safety of iNO in clinical practice and trials for other diseases, we propose a randomized clinical trial of iNO for the adjunctive treatment of severe malaria in Ugandan children.
Hidradeniti s suppurati va (HS) is a chronic infl ammatory cutaneous disease which involves the pilosebaceous-apocrwhich typically presents aft er puberty with painful nodules and abscesses which can form sinus tracts and scars in theapocrine gland-bearing sites of the body. 1 Esti mates of disease prevalence range from 0.0003% to 4%, with youngparti cularly women as the most eff ected group. Racial predilecti on has also been demonstrated, with a higher likeldisease in African American and biracial individuals when compared to whites.1 HS is an under-recognized enti ty, ontaking 7.2 years from symptom onset to formal diagnosis.2 A notable aspect of HS is the profound impact it can have oof life in pati ent's suff ering with the disease, with an increase in depression, pain, and social and work impairment.pathogenesis conti nues to be elucidated but is primarily thought to be due to follicular hyperkeratosis, leading formati on, dilati on, and rupture. This in turn causes infl ammati on, abscess and sinus tract formati on. 1, 4 Whiunderstanding of a role of tumor necrosis factor (TNF) alpha, interleukin (IL)-1, IL-17A, IL-23, C-reacti ve protein (Cinterferon (IFN) gamma have been previously shown, much is sti ll unknown of the molecular involvement of infl ammarkers in HS.1, 2, 4. Currently, management varies from topical treatment, to surgical excision, to prescribing manbiologic medicati ons used for hidradeniti s suppurati va and infl ammatory bowel disease. However, there can be vasvariability in response to these medicati ons, and a proper understanding of the infl ammatory markers involved inpathogenesis will allow for more specifi c treatment, while hopefully avoiding the adverse eff ects related to these isuppressive medicati ons. Thus, in this study we will assess the cytokines, TNF-alpha, IFN-gamma, IFN-alpha, IFN-beta, IIL-12, IL-23, IL-17A, and study their regulati on in HS lesions of pati ents, with the ulti mate goal of identi fying potenti al tafuture therapies and interventi ons.
Reactive astrocytes (RAs) produce chondroitin sulfate proteoglycans (CSPGs) in large quantities after spinal cord injury (SCI) and inhibit axon regeneration through the Rho-associated protein kinase (ROCK) pathway. However, the mechanism of producing CSPGs by RAs and their roles in other aspects are often overlooked. In recent years, novel generation mechanisms and functions of CSPGs have gradually emerged. Extracellular traps (ETs), a new recently discovered phenomenon in SCI, can promote secondary injury. ETs are released by neutrophils and microglia, which activate astrocytes to produce CSPGs after SCI. CSPGs inhibit axon regeneration and play an important role in regulating inflammation as well as cell migration and differentiation; some of these regulations are beneficial. The current review summarized the process of ET-activated RAs to generate CSPGs at the cellular signaling pathway level. Moreover, the roles of CSPGs in inhibiting axon regeneration, regulating inflammation, and regulating cell migration and differentiation were discussed. Finally, based on the above process, novel potential therapeutic targets were proposed to eliminate the adverse effects of CSPGs.
Participants are inoculated with P. falciparum. Panel B participants receive MK-7602 as a single oral dose. Participants will receive artemether/lumefantrine oral tablets as definitive antimalarial treatment. Additional definitive antimalarial treatment may be administered at the investigator's discretion.
Genes encoding the transcription factors controlling the core circadian oscillator (BMAL, Clock, NPAS, Per) and their regulatory targets (Rev-erbα, Rev-erb) have been found in adipose tissue. The circadian pattern of these genes was entrained using restricted feeding. The circadian gene expression profiles were examined in mice and in undifferentiated and adipocyte-differentiated human adipose stem cells following exposure to nuclear hormone receptor ligands (dexamethasone or thiazolidinedione) or 30% fetal bovine serum. All three agents induced the initiation of a cyclic expression profile in representative circadian genes in the human adipose stem cells. The circadian genes studied displayed an oscillatory expression profile, characterized by both a zenith and nadir within a 24-28 hr phase. The circadian gene pattern has been lengthened with use of an inhibitor of glycogen synthase kinase 3 beta. Modulation of the circadian pattern to lengthen or shorten can be used to affect weight gain or loss, respectively.
Participants first receive placebo (BID) for 7 days. After a washout period of 7 days, they then receive lorcaserin (10 mg BID) for 7 days.
Routine geriatric rehabilitation will include a multidisciplinary and individualized treatment plan based on comprehensive geriatric and specific rehabilitation assessments. As a specific control intervention, within 72 hours from admission a nurse without training in MI will handle the patient written information about generic benefits of exercising.
This study is a third-stage project. The first stage is to explore the difference between real and virtual reality natural environment experiences on improving attention and emotion of elders. The one hundred and twenty participants will be randomly assigned to the experimental group (A group with actual experience of natural or B group with virtual reality experience of natural) and control group (actual experience of city). Outcome measures will include attention restoration, emotion, physiological measures, and virtual reality experience. The second stage is to explore the difference between tree element virtual natural environment and tree and water element virtual natural environment experiences on improving attention and emotion of older people. Participants will be randomly assigned to the experimental group (tree element group or tree and water element group) and control group (no intervention). Outcome measures will include attention restoration, emotion, physiological measures, and virtual reality experience. The third stage is to test effects of virtual reality natural environment intervention program on improving attention, cognitive function, anxiety and depression in institutional elderly. Eighty participants will be randomly assigned to the experimental group and control group. The intervention group will last for 8 weeks. Outcome measures will include attention, cognitive function, anxiety and depression, physiological measures, virtual reality e experience, sleep quality and activities of daily living. Contribution: This study aims to understand the effects of virtual natural environment intervention on the psychological symptoms and cognitive function of the elderly.
PURPOSE:A member for treating dermatosis having a base layer containing a two- or multicomponent copolymer of an alkyl ester of acrylate monomer and a monomer having a nonelectrolytic group or cationic electrolytic group in the  side chain thereof containing a specific corticosteroid. CONSTITUTION:A member for external use having a base layer, containing a  two- or multicomponent copolymer of (A) an alkyl acrylate having a 4-12C  alkyl group and (B) a monomer having a nonelectrolytic group and/or cationic  electrolytic group in and side chain thereof and a chemical, and formed on a  carrier, e.g. a plastic film, nonwoven fabric or paper. The component (A) imparts the tackiness and adhesive property to the skin, and the component (B) imparts the cohesive force to the copolymeric layer and improves the release  property and stability of the chemical. The resultant member will not exhibit  the residual paste phenomenon on the skin. A corticosteroid having an alkyl  ester on the carbon atom at the 21-position, etc. is used as the chemical.
BACKGROUND: Direct oral anticoagulants (DOACs) are recommended for patients with atrial fibrillation (AF) given their improved safety profile. Suboptimal adherence to DOACs remains a significant concern among individuals with AF. However, the extent of adherence to DOACs following a cardiovascular or bleeding event has not been fully evaluated.
OBJECTIVE: To evaluate the pattern of adherence trajectories of DOACs after a cardiovascular or bleeding event and to investigate the sociodemographic and clinical predictors associated with each adherence trajectory by using claims-based data.
METHODS: This retrospective study was conducted among patients with AF prescribed with DOACs (dabigatran/apixaban/rivaroxaban) between July 2016 and December 2017 and who were continuously enrolled in the Texas-based Medicare Advantage Plan. Patients who experienced a cardiovascular or bleeding event while using the DOACs were further included in the analysis. The sample was limited to patients who experienced a clinical event such as a cardiovascular or bleeding event while using the DOACs. The clinical events considered in this study were cardiovascular (stroke, congestive heart failure, myocardial infarction, systemic embolism) and bleeding events. To assess adherence patterns, each patient with a DOAC prescription was followed up for a year after experiencing a clinical event. The monthly adherence to DOACs after these events was evaluated using the proportion of days covered (PDC). A group-based trajectory model incorporated the monthly PDC to classify groups of patients based on their distinct patterns of adherence. Predictors associated with each trajectory were assessed using a multinomial logistic regression model, with the adherent trajectory serving as the reference group in the outcome variable.
RESULTS: Among the 694 patients with AF who experienced clinical events after the initiation of DOACs, 3 distinct adherence trajectories were identified: intermediate nonadherent (30.50%), adherent (37.7%), and low adherent (31.8%); the mean PDC was 0.47 for the intermediate nonadherent trajectory, 0.93 for the adherent trajectory, and 0.01 for low adherent trajectory. The low-income subsidy was significantly associated with lower adherence trajectories (odds ratio [OR] = 4.81; 95% CI = 3.07-7.51) and with intermediate nonadherent trajectories (OR = 1.57; 95% CI = 1.06-2.34). Also, nonsteroidal anti-inflammatory drug use was significantly associated with lower adherence trajectories (OR = 5.10; 95% CI = 1.95-13.36) and intermediate nonadherent trajectories (OR = 3.17; 95% CI = 1.26-7.93). Other predictors significantly associated with both nonadherent trajectories are type of DOACs (OR = 0.53; 95% CI = 0.35-0.79), presence of coronary artery disease (OR = 1.89; 95% CI = 1.01-3.55), and having 2 or more clinical events (OR = 1.65; 95% CI = 1.09-2.50).
CONCLUSIONS: Predictors identified provide valuable insights into the suboptimal adherence of DOACs among Medicare Advantage Plan enrollees with AF, which can guide the development of targeted interventions to enhance adherence in this high-risk patient population.
This period will consist on a structured personalised hypocaloric diet containing ready prepared meals with cocoa extract added. Final cocoa extract daily intake will be of 1.4 g.
Hyperuricemia (HUA) is a disorder of uric acid metabolism, which can lead to the formation of gouty arthritis, kidney inflammation and other damages. Previous studies have found that the alcohol extract of Poria cutis can reduce the level of uric acid and protect against kidney injury. Based on network pharmacology, the core targets and main active components of P. cutis intervention in HUA were determined. Most of the potential active ingredients are triterpenoid acids such as tumulosic acid (TA) and eburicoic acid (EA), and the potential targets are TNF and IL-6, which are associated with inflammation. In vitro experiments have shown that TA can significantly inhibit the release of NO, TNF-α and IL-6 in inflammatory RAW264.7 cell culture medium and the expression of TNF-α and IL-6 in RAW264.7 cells. This study suggests that TA based on network pharmacological screening has obvious anti-inflammatory effect on inflammatory RAW264.7 cells and is a promising anti-inflammatory compound.